ka | en
Company Slogan TODO

The study of genomic in patients by hypertrophic cardiomyopathy and their relatives

Author: Tinatin Jokhadze
Keywords: Hypertrophic cardiomyopathy, genome

Hypertrophic cardiomyopathy (HCM) is a genetically determined disease. In 45% of cases of HCM has a family character. This suggests a leading role in development of disease genotype. On this basis, the study emphasizes the variability of the functional characteristics of the genome in patients and their relatives (to identify risk groups).Last closely contacts to search for the means to identify preventive measures and reduce the risk of disease. Were srudied of the functional genome indicators (quantitative structure-chromosome disorders) using lymphocyte cultures of patients with hypertrophic cardiomyopathy and their relatives. Studies conducted both in intact cultures and cultures exposed to the influence of peptide-Bioregulators epithalon, Vilhon and Livagena.As indicated according to the results of the analysis, the cells of the individuals with HCM and their relatives were characterized by higher frequency of spontaneous structural aberrations in comparison with the cells of healthy individuals of related age groups (HCM patients – 4,4+0.9%; relatives – 4,1+0.9%; control group – 1,7+0.5%). The most effective protective action in relation normalization of functional parameters of the genome shows Epithalon for lowering the level of chromosomal instability in patients with hypertrophic cardiomyopathy and relatives of patients with HCM . On the basis of identified protective action Epithalon concludes prospects of its application in the development of preventive measures for individuals at increased risk of morbidity HCM .

Web Development by WebDevelopmentQuote.com
Design downloaded from Free Templates - your source for free web templates
Supported by Hosting24.com